Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome

  title={Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome},
  author={Grace Huang and Andrea D. Coviello},
  journal={Current Opinion in Endocrinology \& Diabetes and Obesity},
  • Grace Huang, A. Coviello
  • Published 1 December 2012
  • Medicine, Biology
  • Current Opinion in Endocrinology & Diabetes and Obesity
Purpose of reviewPolycystic ovarian syndrome (PCOS) is the most common endocrinopathy in premenopausal women. This review discusses the screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with PCOS, highlighting significant recent developments. Recent findingsPCOS is a complex genetic disorder with multiple susceptibility genes as well as environmental factors influencing the expression of various PCOS phenotypes. The first genome-wide… 

Practice Patterns in Screening for Metabolic Disease in Women with PCOS of Diverse Race-Ethnic Backgrounds.

  • M. MottN. KitosA. Coviello
  • Medicine
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2014
Screening rates for metabolic disease in women with PCOS remained low across all race-ethnicities in 2011, and were higher in the endocrine clinic for all metabolic disorders than in other clinics.

Targets to treat metabolic syndrome in polycystic ovary syndrome

The importance of developing strategic interventions to increase the compliance to lifestyle and dietary modification, in addition to appreciation of the emerging pharmaceutical therapeutics available, is concluded.

Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome.

To determine the prevalence of NAFLD and metabolic syndrome in patients with PCOS, and to verify if there is a correlation between non-alcoholic fatty liver disease and metabolic Syndrome in this population, a study conducted at Gynecology Department of Clinical Hospital of Federal University of Parana from April 2008 to January 2009.

Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis

A systematic review and meta-analysis of longitudinal studies linking polycystic ovary syndrome and cardiometabolic disease quantifies this risk, which is important for clinicians to inform patients and to take into account in the cardiovascular risk assessment of women with PCOS.

Role of Statins in PCOS Management

Combined therapy using statin and resveratrol may potentially offer a novel, promising approach aimed at reduction of ovarian hyperandrogenism and cardiovascular risks in women with PCOS.

Metabolic Syndrome: From Human Organ Disease to Fetal Programming

The main outcomes of metabolic syndrome in white adipose tissue are assessed focusing on insulin resistance and adipokines, the cardiovascular system, the liver and ovaries as well as fetal origins; some proposed pharmacological treatments are discussed to provide a better understanding of the related pathways in these secondary findings.

Nonalcoholic fatty liver disease and polycystic ovary syndrome.

  • E. Vassilatou
  • Medicine, Biology
    World journal of gastroenterology
  • 2014
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world comprising a spectrum of liver damage from fatty liver infiltration to end-stage liver

A Study of Serum Soluble CD 163 Levels in Women with Polycystic Ovary Syndrome.

Soluble CD163, which is identified as a marker of inflammation and type II diabetes, is elevated in polycystic ovary syndrome and Elevated sCD163 levels were found to be associated with total testosterone.

History of infertility and risk of type 2 diabetes mellitus: a prospective cohort study

These novel findings suggest a history of infertility, particularly that related to ovulation disorders and tubal blockage, is significantly associated with a higher risk of type 2 diabetes.



Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.

The metabolic syndrome and its individual components are common in PCOS, particularly among women with the highest insulin levels and BMI, and Hyperinsulinemia is a likely common pathogenetic factor for both PCOS and the metabolic syndrome.

Polycystic ovary syndrome: etiology, pathogenesis and diagnosis

Treatment of PCOS is focused on the goals of ameliorating hyperandrogenic symptoms, inducing ovulation and preventing cardiometabolic complications, and ruling out other hyper androgenic or oligo-ovulatory disorders.

Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome.

NAFLD is common in PCOS patients and increased androgen bioavailability may be implicated, in combination with metabolic abnormalities, and Liver evaluation is proposed in PCos patients, especially in those with metabolic syndrome.

Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.

An expert panel in PCOS and CVD reviewed literature and presented recommendations, finding women with PCOS with obesity, cigarette smoking, dyslipidemia, hypertension, impaired glucose tolerance, and subclinical vascular disease are at risk, whereas those with metabolic syndrome and/or type 2 diabetes mellitus are at high risk for CVD.

Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts

At least two of the PCOS susceptibility loci identified in the Chinese PCOS GWAS are also associated with PCOS in European derived populations, and are therefore likely to be important in the aetiology of PCOS regardless of ethnicity.

Polycystic ovary syndrome and cardiovascular disease: a premature association?

  • R. Legro
  • Medicine, Biology
    Endocrine reviews
  • 2003
The existing data suggest that PCOS may adversely affect or accelerate the development of an adverse cardiovascular risk profile, and even of subclinical signs of atherosclerosis, but it does not appear to lower the age of clinical presentation to a premenopausal age group.

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.

  • Medicine, Biology
    Fertility and sterility
  • 2004
PCOS remains a syndrome of ovarian dysfunction along with the cardinal features hyperandrogenism and polycystic ovary (PCO) morphology, and no single diagnostic criterion is sufficient for clinical diagnosis.

Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study.

The well-described cardiovascular/metabolic risk profile in pre- and perimenopausal PCOS women does not entail an evident increase in cardiovascular events during the postmenopausal period.

Polycystic ovary syndrome: Syndrome XX?